Grifols AIt raises its net profit to 177 million euros in the first half of this year, which represents an increase of 387.6% compared to the first semester of 2024, or almost four times more.
In the Hemodervados Company, The revenues of the first semester of the year grew by 7.0% CC, to reach 3,677 Millions of euros, promoted by the solid performance of the Biopharma business, which registered a growth of 8.2% CC.
The adjusted ebitda stood at 876 million euros, which represents an increase of 12.7% CC Regarding the same period of the previous year, with a margin of 23.8%, backed by the company’s products portfolio, continuous improvement initiatives.
From Grifols it emphasizes that the results «are promoted by a second quarter that has registeredor sustained improvements in the main operational and financial indicators. These results reflect the continuous progress in the execution of the company’s value creation plan. and the operational leverage. »
Free cash flow before mergers and acquisitions improved significantly until reaching 30 million euros in positive in the second quarter, which places the figure of the first semester at -14 million euros. This evolution represents an interannual improvement of 182 million euros, mainly driven by Ebitda growth, efficient management of circulating capital and the reduction of financial costs.
Grifols continued to reinforce its financial position, reducing Its leverage ratio up to 4.2x, compared to 4.5x in the anterior quarter and 5.5x in the first half of 2024with a liquidity position of 1.4 billion euros. The company is still focused on continuing to improve its credit profile.
As part of its capital allocation strategy, Grifols successfully completed the exclusion of Biotest from the Frankfurt Bag and raised its shareholding up to 80.32%. This operation, with a total cost of 108 million euros, was fully financed with available financial resources.
The company declared a dividend of 0.15 euros per share, backed by the solid evolution of the underlying results and the continuous generation of free cash flow. This decision reflects Grifols’s firm commitment to compensation to the shareholder.
Guides for the second part of the year
Grifols starts the second half of the year with a solid boost in its main businesses, reaffirming the shared forecasts during the capital Markets Day, held on February 27, 2025. In addition, Improves your Guidance for free cash flow before mergers and acquisitions, placing it between 375 and 425 million euros.
Although the recent depreciation of the US dollar can affect income and EBITDA reported in the second quarter of the year, The company foresees a practically neutral impact on the benefit of the group, leverage and free cash flow before mergers and acquisitions. This forecast is based on the solidity of the underlying business and the implementation of specific efficiency measures.
Nacho Abia, CEO of Grifols, He points out: “The company’s solid performance in the first half of 2025 highlights the consistent execution of our value creation plan. The impulse of the business is evident: in a context of strong underlying demand, we continue to capitalize on the strength of our biopharma unit while we advance in our
strategic priorities ”.
And add the CEO that «although the creation of value will ultimately benefit our shareholders, we remain fully committed to the development of solutions that respond to the needs of the patients, a priority that has defined Grifols for more than 116 years.»